Loading…
← CockpitCompetitor Analysis › STVN Stevanato Group SpAOpen in the cockpit ↗

Stevanato Group SpASTVNCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Italian maker of glass vials, syringes and drug-containment/delivery systems for the pharmaceutical and biotech industry.

Momentum weak 22
Mkt cap
$4.19B
US dollars, full cap
Free float
98%
of shares outstanding
$/day
$19.4M
20-day average traded
Fwd P/E
22.5×
forward earnings
ROIC−WACC
+0.4 pp
WACC 8.7%
Hurdle
+1 pp
Req g minus delivered
Next earnings
113 days
11 Mar 2027
Close · USD$15.36
1D+0.7%
1W+10.4%
1M-19.2%
3M-31.3%
6M-13.5%
YTD-23.7%
1Y-28.6%
ATR %6.9%
Beta0.84
52w lowhigh36.0% off high

What Stevanato does

Italian maker of glass vials, syringes and drug-containment/delivery systems for the pharmaceutical and biotech industry.

Sells containers by the unit to drugmakers, and orders recur as customers fill batches of their drugs, so demand follows their injectable volumes. A founding family controls it through a holding company. Engineering sales of machines used on packaging lines are lumpier, project-style business.

Products and services

  • Glass vials/cartridges/syringes
  • Drug delivery devices (auto-injectors, pens)
  • Engineering (pharma packaging-line equipment)

Customers

  • Biopharma manufacturers (injectables, vaccines)

Where it sits in the supply chain

  • Healthcare
  • Pharma packaging & delivery components
  • Glass primary packaging and drug…

What could go right

  • GLP-1/biologics injectable packaging demand surge
  • Vaccine and biologics vial demand

What could go wrong

  • Customer destocking cycles
  • Raw material (pharma-grade glass) cost volatility

Moat: narrow (customer qualification, IP / patents, switching costs). Packaging components are qualified in customers' regulatory drug filings, making switching costly and slow.

Headquarters: Piombino Dese, Italy · Founded: 1949

Named competitors

Stevanato at a glance

Size Stevanato (STVN) is a United States Health Care company (Medical Specialties) with a market value of $4.19B, the 1303rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $15.36 on 18 Nov 2026.

Performance Over six months the shares fell 13.5%, against +29.6% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd lowest of 21 in its peer set.

Growth Revenue grew 12.0% over the last twelve months (peer median +8.3%); the operating margin is 17.6% (peer median 13.1%).

Valuation It trades at 22.5× forward earnings against a peer median of 20.2× (7th most expensive of 19).

Price implies For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 0.4 points above its cost of capital (8.7% WACC).

Short interest Short interest is 1.8% of the free float (30 Oct 2026).

Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 129STVN 86
Six months, rebased to 100: Stevanato against the median of its 20 peers (local-currency closes).

Stevanato financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$1.45B$1.34B$1.19B$1.17B$1.03B
Revenue growth—+12%+2%+14%—
Gross profit$418M$375M$316M$353M$324M
EBITDA$369M$315M$252M$291M$251M
Net income$163M$158M$127M$157M$150M
Free cash flow$14.4M$25.2M-$159M-$355M-$138M
Capital expenditure$308M$310M$339M$478M$256M
Total debt$533M$551M$444M$440M$233M

Quarterly statements and history in the cockpit →

Stevanato competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+25%+50%+75%-20%0%+20%002223ICUIFIECDNA002432GRALNVSTSHC1SXPMMEDDIA300677603014TECN4203AMBU-BMMSIAXGNLIVNPLSESTVN6-month return →1-month return →
Up and to the right = strong over both horizons. Stevanato is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%25×50×75×002223ICUIFIECDNA002432NVST1SXPMMED300677TECN4203AMBU-BMMSIAXGNSTVNRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Stevanato is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%002223ICUIFIE002432NVSTSHC1SXP300677TECNAMBU-BAXGNSTVNGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Stevanato is the large dot.

Stevanato competitors and peer comparison

Head to head with its named competitors (STVN vs WST vs GXI.DE vs 1SXP.DE)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Stevanato STVN$4.19B-13%+12%18%22.5×13.1%
West Pharmaceutical Services WST$28.1B+32%+13%23%40.2×25.8%
Gerresheimer GXI.DE$1.26B+21%+9%-4%16.0×57.0%
SCHOTT Pharma AG & Co. KGaA 1SXP.DE$3.73B+32%+4%15%23.0×12.7%

How Stevanato compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Stevanato against its 20 peers (data as of 18 Nov 2026)
MeasureSTVNPeer medianRank in peer set
1-month return-19.2%+5.2%lowest of 21
6-month return-13.5%+29.6%2nd lowest of 21
Distance from 52-week high-36.0%-18.0%4th lowest of 21
Revenue growth (TTM)+12.0%+8.3%8th highest of 21
Operating margin17.6%13.1%4th highest of 20
Forward P/E22.5×20.2×7th most expensive of 19
Growth the price implies (Req g, 7 yrs)13.1%9.3%6th most demanding of 17
Growth delivered (Del g)+12.1%+8.2%2nd highest of 17
Hurdle (Req g minus delivered)+1.0 pp+1.6 pp8th least demanding of 17
ROIC minus cost of capital+0.4 pp+1.5 pp8th lowest of 19
EV / EBITDA12.5×13.3×6th cheapest of 13
Net debt / EBITDA1.1×0.1×4th most indebted of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Stevanato STVNUnited States$4.19B-13%+12%18%22.5×13.1%+12.1%
Jiangsu Yuyue Medical Equipment & Supply 002223.SZChina$4.18B-3%-1%13%20.0×4.9%+3.4%
ICU Medical ICUIUnited States$4.46B+38%-6%8%19.4×18.9%+11.9%
Fielmann FIE.DEGermany$3.92B-3%+3%14%17.1×-5.5%+11.3%
CareDx CDNAUnited States$3.91B+252%+39%1%50.6×n/an/a
Andon Health 002432.SZChina$3.86B-24%-30%-26%16.1×-6.6%-7.4%
GRAIL GRALUnited States$4.59B+67%+17%-332%n/an/an/a
Envista NVSTUnited States$3.81B0%+10%12%14.7×4.8%+7.1%
Sotera Health SHCUnited States$4.65B+5%+7%37%15.7×14.4%+7.3%
SCHOTT Pharma AG & Co. KGaA 1SXP.DEGermany$3.73B+32%+4%15%23.0×12.7%+11.0%
MiniMed MMEDUnited States$4.78B+46%+14%14%26.3×n/an/a
DiaSorin DIA.MIItaly$4.81B+24%-3%24%20.5×4.1%+6.3%
Intco Medical Technology 300677.SZChina$4.82B-2%+33%20%18.5×-3.5%-6.4%
Shandong Weigao Blood Purification Products 603014.SSChina$3.63B-1%+4%n/a20.4×-1.2%+8.1%
Tecan TECN.SWSwitzerland$3.60B+59%-4%1%35.5×45.4%+3.8%
Sumitomo Bakelite 4203.TJapan$3.50B+7%+15%13%15.9×8.6%+8.9%
Ambu A/S AMBU-B.CODenmark$3.47B+31%+7%13%28.8×10.0%+10.0%
Merit Medical Systems MMSIUnited States$5.15B+33%+9%14%19.1×12.6%+9.5%
Axogen AXGNUnited States$3.40B+33%+24%-5%87.3×52.6%+14.9%
LivaNova LIVNUnited States$5.21B+28%+12%15%20.9×14.2%+8.2%
Pulse Biosciences PLSEUnited States$3.37B+76%+1,637%-5,821%n/an/an/a

Questions

Who are Stevanato's main competitors?
Named competitors: West Pharmaceutical Services (WST), Gerresheimer AG (GXI.DE), Schott Pharma (1SXP.DE). The cockpit's measured peer set (industry) also includes Jiangsu Yuyue Medical Equipment & Supply (002223.SZ), ICU Medical (ICUI), Fielmann (FIE.DE), CareDx (CDNA), Andon Health (002432.SZ), GRAIL (GRAL).
Is Stevanato expensive compared with its peers?
On forward p/e it trades at 22.5× against a peer median of 20.2×, 7th most expensive of 19 in its peer set. For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Stevanato stock performed?
Over six months to 18 Nov 2026 the shares returned -13.5% against +29.6% for the median peer; over one year -28.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.